We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Testing > Content Piece

In Arkansas, Four Cannabis Companies Are Accused of THC Inflation

By Leo Bear-McGuinness

Published: Jul 28, 2022   

Complete the form below and we will email you a PDF version of "In Arkansas, Four Cannabis Companies Are Accused of THC Inflation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Three cannabis cultivation companies and one testing lab are facing a class action lawsuit in Arkansas. The allegation? That all four conspired to defraud medical cannabis patients by inflating cannabis potency testing results.

The lawsuit was filed on July 12 by three medical cannabis patients, after they noticed “that some marijuana was more potent than others, despite being labeled as having similar amounts of THC,” according to the lawsuit that was first reported by Law360.

The four affected companies are the cultivators Bold, Osage Creek Cultivation, and Natural State Medicinals, and the testing lab Steep Hill Arkansas, which is a subsidiary of Steep Hill Inc.

“Each Defendant has conducted or participated in the conduct of the affairs of Osage, NSM AND BOLD through a pattern of racketeering activity,” the lawsuit reads.

The RICO lawsuit says that the four companies were aware that cannabis products with higher THC levels could command higher prices. With this knowledge, the suit alleges, the companies colluded to artificially raise the THC potencies of certain products to sell to medical cannabis patients.

“The racketeering activities of Defendants directly and proximately injured the Plaintiff and the Class’ property by selling them Regular marijuana for a much higher Premium price,” the suit continues.

Analytical Cannabis has reached out to all four affected companies for comment.

 

Like what you just read? You can find similar content on the topic tags shown below.

Science & Health Testing

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement